Esophageal Replacement With a Decellularized Human Esophagus Graft

Trial statusNot yet recruiting
Trial phasePhase 1, Phase 2
Trial typeInterventional
Biological sexAll
Age18-65
SponsorAssistance Publique - Hôpitaux de Paris

About this trial

The aim of the study is to analyze over a 12 month-period, the safety and the efficacy of a circumferentiel oesophageal replacement of the esophagus by a decelularized human esophagus, in 24 patient with a short esophageal stenosis refractory to endoscopic dilatations.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age: 18 to 65

Caustic, traumatic, anastomotic, post-operative, radiation-induced or post-endoscopic (mucosal resection, submucosal dissection) benign esophageal stricture refractory to endoscopic dilatation.

For women: effective contraception for the entire duration of the study (from signature of consent to end of follow-up)

Affiliated or beneficiary of a social security scheme.

Disqualifiers

Weight loss > 10% of body weight over last 3 months

Stenosis > 5 cm in length

Multiple strictures

Esophageal mouth stenosis

Trial design

Design model

Single group

Treatments tested in this trial

  • Replacement of the esophagus with a decellularized human esophagus graft

    Other intervention

    The Decellularized Human Esophagus (DHE) will be surgically implanted under general anesthesia via right or left thoracotomy or cervicotomy, depending on the location of the stenosis, to replace the esophageal defect created by resection of the stenosis. An omentoplasty is performed laparoscopically beforehand to provide secondary coverage of the graft area. A temporary esophageal stent is placed endoscopically to cover the DHE and the two anastomoses for a period of 3 months, to prevent the development of an anastomotic fistula and stenosis of the graft area.

Treatment groups

24 Participants
are divided into 1 treatment group
Group A: Esophagus replacementExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Morbidity/mortality

Safety criterion : morbidity/mortality defined by : Refractory stenosis, leaking, sepsis, stent migration, death, complete rupture of anastomoses, uncontrolled mediastinal sepsis requiring removal of the substitute and/or esophagectomy, delamination of the tissue graft, tracheobronchial wound intra-operatively or oesotracheal fistula postoperatively, upper digestive obstruction after stent removal preventing any attempt to dilate the graft zone, or upper digestive obstruction after stent removal preventing any attempt to dilate the graft zone

Time frame
At 3 months after surgery
2

Nutritional autonomy

Efficacy criterion: nutritional autonomy at 12 months after esophageal replacement defined as stable weight with exclusive oral nutrition and without esophageal stenting for at least 3 months, and without persistent symptomatic scar stenosis after 5 endoscopic dilatation sessions

Time frame
At 12 months after esophageal replacement

Secondary outcomes

1

Safety of the procedure

The morbidity and mortality of the procedure will be defined by the occurrence of a complication such as leakage, sepsis, recurrent paralysis, esophageal stricture refractory to dilatation, anastomotic fistula, sepsis, esophageal perforation, cardio-respiratory complication (pneumopathy, pleural effusion, pulmonary embolism, AC/FA, infarction), death, tissue graft disintegration, postoperative tracheobronchial wound or oesotracheal fistula, or upper digestive obstruction after stent removal preventing any attempt to dilate the graft zone), for 12 months from the date of surgery.

Time frame
At 12 months after esophageal replacement
2

Presence of complete re-epithelialization, and integration into the native esophagus

Assessed by endoscopy

Time frame
At 3 months after surgery
3

Presence of complete re-epithelialization, and integration into the native esophagus

Assessed by CT scan with gel ingestion and intravenous contrast injection

Time frame
At 12 months after surgery
4

Normal bolus transit

Assessed by barium deglutition

Time frame
At 6 months after surgery

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: